Sanofi logo

Latest headlines

Sanofi News

The latest Sanofi (SNY) news, aggregated as it breaks. News moves sentiment and sentiment moves price, so read these SNY headlines next to the live Sanofi Fear and Greed Index.

Latest Sanofi Headlines60

Press Release: Sanofi's subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector

globenewswire.com · Jul 10, 2026

US FDA approves Sanofi's wearable injector form of blood cancer drug

reuters.com · Jul 10, 2026

EU seeks feedback on Sanofi's commitments addressing suspected anti-competitive behaviour

reuters.com · Jul 8, 2026

SNY's Nexviazyme Meets Goals in Infantile-Onset Pompe Disease Study

zacks.com · Jul 1, 2026

Press Release: Availability of the aide-mémoire for Q2 2026 results

globenewswire.com · Jul 1, 2026

Bargain Hunters: These 3 High-Yielding Stocks Recently Hit New 52-Week Lows

fool.com · Jun 30, 2026

Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

fool.com · Jun 30, 2026

EU Commission opens antitrust probe into Sanofi's flu vaccine campaign

reuters.com · Jun 26, 2026

Is AbbVie a Buy After Its Purchase of Apogee?

fool.com · Jun 25, 2026

Sanofi: Dupixent Risks Overstated, Valuation Disconnect Creates Opportunity

seekingalpha.com · Jun 25, 2026

Press Release: Sanofi Foundation opens new chapter centered on future generations

globenewswire.com · Jun 25, 2026

EU Clears SNY's Cenrifki for Secondary Progressive Multiple Sclerosis

zacks.com · Jun 23, 2026

Sanofi Multiple Sclerosis Drug Gets EU Approval

wsj.com · Jun 23, 2026

Press Release: Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia

globenewswire.com · Jun 23, 2026

Can Sanofi Rely on Dupixent to Drive Long-Term Revenue Growth?

zacks.com · Jun 22, 2026

Press Release: Sanofi appoints Paulo Fontoura as Global Head of R&D

globenewswire.com · Jun 22, 2026

Press Release: Sanofi's Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma

globenewswire.com · Jun 19, 2026

Sanofi 'Strong Buy': Continued Dupxient Sales Growth And Sarclisa OBI First

seekingalpha.com · Jun 15, 2026

Sanofi Wins FDA Nod for Expanded Use of T1D Drug in Children

zacks.com · Jun 15, 2026

Sanofi: Information concerning the total number of voting rights and shares – May 2026

globenewswire.com · Jun 15, 2026

FDA approves Sanofi's drug for stage 3 type 1 diabetes in children

reuters.com · Jun 12, 2026

Wayrilz (rilzabrutinib, Sanofi) Positioned to Define Third-Line Treatment in Warm Autoimmune Hemolytic Anemia (w-AIHA) as IMAAVY (niopcalimab, Jonhson & Johnson) Follows Closely with Positive Data Announcement at EHA 2026

globenewswire.com · Jun 12, 2026

Sanofi, An Argenx Rival, Bites The Dust — But A Third Biotech Took The Biggest Hit

investors.com · Jun 10, 2026

Sanofi Ends Late-Stage Study on Neurology Drug Over Weak Results

zacks.com · Jun 10, 2026

Sanofi ends Phase 3 riliprubart trial after weak interim results

reuters.com · Jun 10, 2026

Sanofi to Stop Late-Stage Study of Immune-Disorder Drug

wsj.com · Jun 10, 2026

Press Release: Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy

globenewswire.com · Jun 10, 2026

Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration

globenewswire.com · Jun 9, 2026

Sanofi Wins EU Nod for Subcutaneous Sarclisa in Multiple Myeloma

zacks.com · Jun 8, 2026

Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi

businesswire.com · Jun 5, 2026

Sanofi Stock Falls 6% in 3 Months: Should You Buy, Sell or Hold?

zacks.com · Jun 4, 2026

Press Release: Sanofi launches 2026 global employee stock purchase plan

globenewswire.com · Jun 4, 2026

Sanofi Chooses Snowflake to Accelerate its AI-Powered Drug Development

businesswire.com · Jun 2, 2026

FDA Grants Priority Review to SNY's Filing for Gaucher Disease Drug

zacks.com · May 29, 2026

Press Release: Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease

globenewswire.com · May 28, 2026

Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails

zacks.com · May 22, 2026

Sanofi: Information concerning the total number of voting rights and shares - April 2026

globenewswire.com · May 19, 2026

Teva Stock Up More Than 100% in a Year: Time to Buy, Hold or Sell?

zacks.com · May 19, 2026

Sanofi says rare lung disease drug outperforms standard care in trial

reuters.com · May 18, 2026

Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD

globenewswire.com · May 18, 2026

My Top 5 Dividend Stocks For May

seekingalpha.com · May 16, 2026

3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally

fool.com · May 13, 2026

Sanofi: Great Yield And Plenty Of Upside Potential

seekingalpha.com · May 11, 2026

DNLI Q1 Loss Narrower Than Expected, Avlayah Approval Boosts Prospects

zacks.com · May 8, 2026

Sanofi asks to pull diabetes drug out of FDA voucher program, STAT News reports

reuters.com · May 6, 2026

Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1

prnewswire.com · May 6, 2026

Blackstone's $400 Million Bet on Teva: What Does the Smart Money Know That Most Investors Don't?

fool.com · Apr 30, 2026

Press Release: Annual General Meeting of April 29, 2026 - Belén Garijo appointed as Director and Chief Executive Officer of Sanofi

globenewswire.com · Apr 29, 2026

Giants Costco, Sanofi, and SAP Raise Dividends by Over 10%

marketbeat.com · Apr 28, 2026

3 Healthcare Stocks That Pay You a Dividend While You Wait for a Recovery

fool.com · Apr 25, 2026

Press Release: Sanofi successfully prices 2.3 billion of bond issue

globenewswire.com · Apr 24, 2026

Press Release: Sanofi's Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses

globenewswire.com · Apr 24, 2026

SNY & REGN's Dupixent Wins FDA Nod for Pediatric Use in Urticaria

zacks.com · Apr 23, 2026

SNY's Tzield Gets FDA Nod for Kids, Sarclisa SC BLA Faces Delay

zacks.com · Apr 23, 2026

Sanofi Tops Q1 Earnings Estimates as Dupixent & New Drugs Drive Growth

zacks.com · Apr 23, 2026

Sanofi Posts Higher Sales Amid Leadership Transition

wsj.com · Apr 23, 2026

Sanofi's first quarter earnings edges past estimates ahead of CEO change

reuters.com · Apr 23, 2026

Press Release: Sanofi and Regeneron's Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria

globenewswire.com · Apr 22, 2026

Press Release: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children

globenewswire.com · Apr 22, 2026

Press Release: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US

globenewswire.com · Apr 22, 2026

Why Is Sanofi Up or Down Today?

When Sanofi (SNY) moves sharply, the reason is almost always in the headlines above. Earnings, guidance, analyst upgrades and downgrades, product news and macro data are the usual drivers of a SNY move on the day. The feed shows what broke and when, and the sentiment tag on each story shows whether the coverage skews positive or negative, so you can see at a glance why Sanofi is up or down today.

How Sanofi News Affects the Price

News does not move the Sanofi (SNY) price directly, it moves sentiment, and sentiment moves price. A run of negative headlines pulls the Sanofi Fear and Greed Index toward fear, while positive coverage pushes it toward greed, often before the price has fully reacted. A surprise story usually shows up first as a spike in Sanofi trading volume. That is the chain to watch: headline, sentiment, volume, then the SNY price.

Trade the Sanofi News With Sentiment

Headlines tell you what happened; the Fear and Greed Index tells you how the crowd is reacting. Watch Sanofi trading volume spike on a big story, check the Sanofi price history for context, follow the live SNY price, see the Sanofi price prediction, and read the Sanofi Fear and Greed Index for mood.

How do you feel about Sanofi?

1D

Frequently asked questions

Why is Sanofi up or down today?
Sanofi (SNY) moves on news, and the headlines above are the fastest way to see what is driving SNY today, from earnings, guidance and analyst moves to the broader market mood. Cross-check the reaction against the live Sanofi Fear and Greed Index and SNY trading volume.
What is the latest Sanofi news?
The newest Sanofi (SNY) headlines are listed above, most recent first, each linking to the original source. We pull the last 60 stories so you can scroll the full recent SNY news cycle in one place.
Where does Sanofi news come from?
We aggregate Sanofi (SNY) headlines from financial news wires and refresh them continuously. Each headline links straight to the original source.
How often is Sanofi news updated?
Continuously. The Sanofi (SNY) feed refreshes as new stories are published, so the headlines at the top are the freshest available.
How does Sanofi news relate to its Fear and Greed Index?
News drives sentiment, and sentiment drives price. A run of negative headlines tends to push the Sanofi Fear and Greed Index toward fear, positive coverage toward greed. Reading them together is how you separate noise from a real shift in mood.

Headlines are aggregated from third-party sources and link to the original publishers. CFGI does not author or endorse them.

About CFGI

The per-asset sentiment record.

CFGI is a market sentiment data company that scores crowd emotion from 0 to 100 across crypto and stock markets. Crypto readings cover the whole market and hundreds of individual assets across 15-minute, 1-hour, 4-hour and daily views. The stock index gives a live daily reading for wider stock market sentiment.

Every CFGI score is built from 10 indicators: price, volatility, volume, impulse, technical analysis, social media, dominance, search interest, whale movements and order book pressure. The same data powers our API, alerts and embeddable widgets.